Edition:
United Kingdom

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

0.37USD
17 Sep 2019
Change (% chg)

-- (--)
Prev Close
$0.37
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
181,152
52-wk High
$6.73
52-wk Low
$0.25

Latest Key Developments (Source: Significant Developments)

Conatus Pharmaceuticals Reports Q2 2019 Results
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - Conatus Pharmaceuticals Inc ::CONATUS PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROGRAM UPDATES.Q2 REVENUE $10.8 MILLION VERSUS $8.8 MILLION.QTRLY LOSS PER SHARE $0.02.  Full Article

Conatus To Explore Strategic Alternatives, To Reduce Staff By About 40%
Monday, 24 Jun 2019 

June 24 (Reuters) - Conatus Pharmaceuticals Inc ::CONATUS TO EXPLORE STRATEGIC ALTERNATIVES AND IMPLEMENT RESTRUCTURING PLAN.CONATUS PHARMACEUTICALS INC - CONATUS IS IMPLEMENTING A RESTRUCTURING PLAN THAT INCLUDES REDUCING STAFF BY APPROXIMATELY 40%.CONATUS PHARMACEUTICALS INC - SUSPENDING DEVELOPMENT OF ITS INFLAMMASOME DISEASE CANDIDATE, CTS-2090.CONATUS PHARMACEUTICALS INC - PROJECTING A YEAR-END 2019 NET BALANCE OF CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF BETWEEN $10 MILLION - $15 MILLION.  Full Article

Conatus Pharma Reports Q1 Loss Per Share $0.14
Thursday, 2 May 2019 

May 2 (Reuters) - Conatus Pharmaceuticals Inc ::CONATUS PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROGRAM UPDATES.Q1 REVENUE $7.0 MILLION VERSUS REFINITIV IBES ESTIMATE OF $8.3 MILLION.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $33.8 MILLION AT MARCH 31, 2019, COMPARED WITH $40.7 MILLION AT DECEMBER 31, 2018.QTRLY LOSS PER SHARE $0.14.Q2 EARNINGS PER SHARE VIEW $-0.07 -- REFINITIV IBES DATA.  Full Article

Conatus Announces Results From Encore-Ph Phase 2B Clinical Trial
Wednesday, 5 Dec 2018 

Dec 5 (Reuters) - Conatus Pharmaceuticals Inc ::CONATUS ANNOUNCES RESULTS FROM ENCORE-PH PHASE 2B CLINICAL TRIAL IN NASH CIRRHOSIS.CONATUS PHARMACEUTICALS INC - CLINICALLY MEANINGFUL IMPROVEMENTS IN PORTAL HYPERTENSION IN HIGH RISK COMPENSATED CIRRHOSIS PATIENTS.CONATUS PHARMACEUTICALS INC - CHANGES IN HVPG FROM BASELINE TO WEEK 24 DID NOT MEET PRIMARY ENDPOINT.CONATUS PHARMACEUTICALS INC - CHANGES IN HVPG FROM BASELINE TO WEEK 24 SHOWED TRENDS CONSISTENTLY FAVORING EMRICASAN COMPARED WITH PLACEBO.CONATUS PHARMACEUTICALS INC - EMRICASAN WAS GENERALLY WELL-TOLERATED IN ENCORE-PH CLINICAL TRIAL.CONATUS PHARMACEUTICALS INC - OVERALL SAFETY PROFILE WAS SIMILAR IN EMRICASAN AND PLACEBO GROUPS..  Full Article

Conatus Pharmaceuticals Reports Q3 Revenue $7.7 Million
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Conatus Pharmaceuticals Inc ::CONATUS PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROGRAM UPDATES.Q3 REVENUE $7.7 MILLION VERSUS $9.6 MILLION.Q3 REVENUE VIEW $9.8 MILLION -- THOMSON REUTERS I/B/E/S.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $49.6 MILLION AT SEPT 30 VERSUS $74.9 MILLION AT DEC 31, 2017.  Full Article

Conatus Pharmaceuticals Q4 Revenue $8.8 Million
Wednesday, 7 Mar 2018 

March 7 (Reuters) - Conatus Pharmaceuticals Inc ::CONATUS PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROGRAM UPDATES.Q4 REVENUE $8.8 MILLION VERSUS $800,000.QTRLY ‍LOSS PER SHARE $0.15​.Q4 EARNINGS PER SHARE VIEW $-0.17 -- THOMSON REUTERS I/B/E/S.  Full Article

Conatus Pharmaceuticals reports Q3 revenue of $9.6 million
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Conatus Pharmaceuticals Inc :Conatus Pharmaceuticals Inc reports third quarter 2017 financial results and program updates.Q3 revenue $9.6 million.Q3 revenue view $16.1 million -- Thomson Reuters I/B/E/S.Conatus Pharmaceuticals Inc - qtrly ‍net loss per share $0.13.  Full Article

EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC
Wednesday, 18 Oct 2017 

Oct 19 (Reuters) - Conatus Pharmaceuticals Inc :EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC.Conatus Pharmaceuticals - ‍continue to evaluate potential internal, external opportunities with goal of announcing initial pipeline expansion plans later in 2017​.  Full Article

Photo

Salini working to resolve Natixis risk to Italian building deal

ROME/MILAN Last minute efforts are under way to remove a hurdle posed by French bank Natixis to a plan by Salini Impregilo to create an Italian construction champion, sources close to the matter said.